Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22497997 | 0.87 | IRAK4 (0.36) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| SCHEMBL22498089 | 0.78 | PIK3CA (0.39) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| SCHEMBL22235254 | 0.78 | IRAK4 (0.38) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| SCHEMBL22234923 | 0.75 | IRAK4 (0.52) | IRAK4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31210435 | 0.75 | MEN1 (0.30) | — | |
| SCHEMBL22235015 | 0.71 | IRAK4 (0.41) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| SCHEMBL22235859 | 0.70 | IRAK4 (0.40) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| Lithium SCHEMBL29651916 | 0.69 | IRAK4 (0.45) | IRAK4PIK3CAPIK3R1 | |
| SCHEMBL22235555 | 0.69 | IRAK4 (0.41) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 | |
| SCHEMBL22234779 | 0.69 | IRAK4 (0.41) | IRAK4PIK3CAPIK3R1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-09-22 | — | — | US | disclosed |
| EP-3947374-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020200898-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020200898-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, LTB4R | IRAK4 522/4885PIK3CA 2417/4885PIK3R1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.